Our Pipeline — What We’re Working on at Chemvet Group
We are frequently asked: What do you actually have in development, and what do you have on the way to market?
At Chemvet Group, more than 125 dedicated scientists, veterinarians, regulatory specialists and other employees work every day to transform scientific insight into biological medicines. The development of biological medicines is a long and resource-intensive process involving research, product development, clinical studies, regulatory review and manufacturing preparation before a product can become commercially available.
The overview below provides a snapshot of Chemvet Group’s current biological medicines pipeline and reflects only part of our overall development activities. In parallel, Chemvet Group is developing products within pet care and specialised feed supplements for production animals. These activities are not included in this overview.
The pipeline illustrates our current position and demonstrates the commercial progress Chemvet Group continues to make within animal health.
Important notice: This overview has been prepared for informational purposes only and constitutes neither product marketing material, a regulatory statement nor a guarantee of future product availability. All products shown remain subject to ongoing development, regulatory approval processes and manufacturing capacity. Launch targets represent anticipated first-country marketing authorisations and may change without prior notice.
Medicine Product Pipeline — Phase Completion — Chemvet Group
Ranked by earliest market entry · Launch target = first country marketing authorisation · Ext. registration not yet initiated for any product · Suivac CCR ext. registration scheduled March 2027
| Product |
Target pathogens |
Category |
Novel? |
Dev. |
Prod. Tech |
Preclinical |
Clinical |
Int. Reg. Docs |
Ext. Registration |
Launch Target * |
| Suivac CCRSows |
E. coli
Cl. perfringens
Cl. difficile
Rotavirus |
Vaccine |
Partly |
✓ Complete |
✓ Complete |
✓ Complete |
✓ Complete |
✓ Complete |
Sched March 2027 |
2027/2028 |
| Horned CCCRCows |
E. coli
Cl. perfringens
Cl. difficile
Rotavirus
Coronavirus |
Vaccine |
Partly |
✓ Complete |
✓ Complete |
✓ Complete |
✓ Complete |
85% |
Not initiated |
2028 |
| Canvac ADogs |
Aujeszky virus |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
✓ Complete |
50% |
75% |
Not initiated |
2028 |
| Horned BPVCows |
Bovine papilloma virus |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
✓ Complete |
✓ Complete |
65% |
Not initiated |
2028 |
| FishFagSalmon |
Aeromonas salmonicida |
Phage |
Yes |
✓ Complete |
✓ Complete |
✓ Complete |
50% |
▶ Started |
Not initiated |
2028 |
| BEE EndolysinsHoneybees |
American foulbrood
(Paenibacillus larvae) |
Endolysin |
Yes |
✓ Complete |
✓ Complete |
✓ Complete |
— |
▶ Started |
Not initiated |
2029 |
| Equine BPVHorses |
Bovine papilloma virus |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
50% |
— |
▶ Started |
Not initiated |
2029 |
| Horned CryptoCows |
Cryptosporidium parvum |
Vaccine |
Partly |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| Suivac PCV2Sows |
Next gen. porcine
circovirus type 2 |
Vaccine |
Partly |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| PRV-1 DNA vacSalmon |
Piscine orthoreovirus
type 1 |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| PRV-3 DNA vacTrout/Salmon |
Piscine orthoreovirus
type 3 |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| Carp SVC vacCarp |
Spring Viremia of Carp
(Carp sprivivirus) |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| mRNA platformMultiple |
— |
Vaccine |
Yes |
✓ Complete |
✓ Complete |
— |
— |
▶ Started |
Not initiated |
TBD |
| Burn wound EndolysinHumans |
Multi Drug Resistant
Klebsiella Isolates |
Endolysin |
In process |
▶ Started |
▶ Started |
— |
— |
▶ Started |
Not initiated |
TBD |
| Snake antivenomHumans/Veterinary |
Snake bite
neutralization sera |
Antisera |
In process |
▶ Started |
— |
— |
— |
▶ Started |
Not initiated |
TBD |
| X-biological IBD/ColitisHumans |
IL-10 induction
antimicrobial peptide
production
intestinal barrier
enhancement |
Biological |
Yes |
▶ Started |
▶ Started |
— |
— |
— |
Not initiated |
TBD |
✓ Complete
▶ Started
% In progress
— Not started
Sched. date
2027/28
2029 launch
TBD
